Armata Pharmaceuticals (ARMP) Interest Expenses (2013 - 2026)

Armata Pharmaceuticals has disclosed Interest Expenses across 13 years of filings, most recently posting $5.6 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at $5.6 million, up 54.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.5 million (up 48.1% YoY), and the FY2025 annual result was $16.6 million, up 54.44% from the prior year.
• Interest Expenses came in at $5.6 million for Q1 2026 at Armata Pharmaceuticals, up from $4.8 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $5.6 million in Q1 2026 to a low of $1.2 million in Q3 2023.
• The 4-year median for Interest Expenses is $3.3 million (2024), against an average of $3.2 million.
• Across the five-year window, Interest Expenses surged 148.55% in 2024 and soared 40.1% in 2025, its largest moves.
• Armata Pharmaceuticals' Interest Expenses stood at $1.4 million in 2023, then surged by 126.21% to $3.3 million in 2024, then soared by 47.38% to $4.8 million in 2025, then climbed by 15.0% to $5.6 million in 2026.
• The last three Interest Expenses figures came in at $5.6 million (Q1 2026), $4.8 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.